Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. XENE
2. HUBS
3. SPY
4. AUTO
5. AAPL
6. AZN
7. TRMD
8. RARE
9. INTU
10. IQST

Go back to Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
(NASDAQ: AVIR) Delayed: 5.26 --0 (-0%)
Previous Close $5.26    52 Week High $2.00 
Open $5.26    52 Week Low $1.15 
Day High $5.26    P/E N/A 
Day Low $5.26    EPS $0.00 
Volume 1,020